Cepheid has received emergency authorization from the Food and Drug Administration to use its rapid molecular test for point-of-care patients that can detect coronavirus in 45 minutes. This is the first coronavirus that can be conducted entirely at the point of care for patients and deliver results in less than an hour. Tests are typically sent to central reference labs that can take several days to deliver results.
Medical take a patient's coronavirus test during a trial run for a new FEMA drive-thru coronavirus testing clinic at CVS at 720 Boston Turnpike in Shrewsbury, MA on March 19, 2020.Cepheid has received emergency authorization from the Food and Drug Administration to use its rapid molecular test for point-of-care patients that can detect coronavirus in 45 minutes.
This is the first coronavirus that can be conducted entirely at the point of care for patients and deliver results in less than an hour.Diagnostics company Cepheid on Saturday said it has received emergency authorization from the U.S. Food and Drug Administration to use its rapid molecular test for point-of-care patients that can detect the virus that causes COVID-19 in 45 minutes.
This is the first coronavirus test that can be conducted entirely at the point-of-care for patients and deliver results in less than an hour. Typically, tests are sent to central reference labs that can takeThe test, called SAR-CoV-2 Xpert Xpress, was developed by Cepheid, a Sunnyvale, California, company was designed to detect SARS-CoV-2, the virus that is causing COVID-19.
Cepheid uses a testing machine called GeneXpert that can run a full test in 45 minutes. There are currently more than 23,000 automated GeneXpert systems worldwide, with nearly 5,000 of them in the U.S., Cepheid said in a statement."During this time of increased demand for hospital services, clinicians urgently need an on-demand diagnostic test for real-time management of patients being evaluated for admission to health-care facilities.
Cepheid President Warren Kocmond added that its automated systems "do not require users to have specialty training" to perform the tests.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA approves new test that could detect coronavirus in about 45 minutesThe FDA announced its approval of the use of the first rapid diagnostic test that could detect coronavirus in approximately 45 minutes. Authorization was made Friday and tests will begin shipping next week, according to the company manufacturing the tests
続きを読む »
Philippines confirms 45 new coronavirus cases, bringing total to 307The Philippines' health ministry reported 45 more confirmed cases of corona...
続きを読む »
Joe: Trump's 'big' coronavirus FDA news is yet another 'overpromise'Joe Scarborough comments on the president's latest briefing on the coronavirus outbreak, calling the announcement of using a malaria drug for treatment another 'overpromise' from the administration.
続きを読む »
Trump touts chloroquine for 'immediate' use treating coronavirus, but FDA wants to see the data firstPresident Trump said Thursday that the antimalarial drug chloroquine had shown “very encouraging early results” treating COVID-19 and will be rolled out “almost immediately” to help fight the growing coronavirus outbreak. But FDA Commissioner Stephen Hahn cautioned that chloroquine had not yet been approved
続きを読む »
Transcript: Full Transcript With FDA Commissioner Stephen HahnFDA Commissioner Stephen Hahn speaks with NPR's David Greene about the development of a vaccine and the use of existing drugs to treat COVID-19. Here, a transcript of their full interview.
続きを読む »
FDA: Those who donate blood 'are contributing immeasurably'The FDA is urging Americans to donate blood, saying those who do 'are contributing immeasurably to the public health of our nation.'
続きを読む »